proteomic changes upon treatment with semaglutide in individuals with obesity - Nature Medicine Semaglutide as a GLP-1 Agonist:

Labarrere and Kassab, 2021

Clinically, AKI may arise from a variety of causes, encompassing sepsis, ischemia/reperfusion (I/R) injury, and exposure to different nephrotoxin, among others (Vijayan, 2021

Researchers found that people prescribed semaglutide, the active ingredient in Wegovy, were 50% more likely to be diagnosed with a hair-loss condition compared to those taking another weight management drug called Contrave (bupropion-naltrexone)

Off-label drug use is common in medicine

We refer readers to section III.C.2.d.(2) of this final rule for further discussion on how we aligned quality measures we other CMS programs